Investigating the Role of Circulating Tumor Cells in Gastric Cancer: A Comprehensive Systematic Review and Meta-Analysis Publisher Pubmed



Eskandarion MR¹ ; Eskandarieh S² ; Tutunchi S³ ; Shakoori Farahani A⁴ ; Shirkoohi R¹ Show Affiliations
Source: Clinical and Experimental Medicine Published:2024

Abstract

Investigating the role of circulating tumor cells (CTCs) and their characteristics is still controversial in patients with gastric cancer (GC). Therefore, in this study, to provide a comprehensive review and meta-analyses of the literature on association of CTCs with gastric cancer, Scopus, Web of Science, Embase, and Medline were searched for systematic reviews and meta-analyses conducted during February 2022 using the keywords. Risk of bias, hazard ratios (HRs), and risk differences (RD) were assessed. Forty-five studies containing 3,342 GC patients from nine countries were assessed. The overall prevalence of CTC in GC was 69.37% (60.27, 77.78). The pooled result showed that increased mortality in GC patients was significantly associated with positive CTCs, poor overall survival (HR = 2.73, 95%CI 2.34–3.24, p < 0.001), and progression-free survival rate (HR = 2.78, 95%CI 2.01–3.85, p < 0.001). Subgroup analyses regarding markers, detection methods, treatment type, presence of distance metastasis, presence of lymph node metastasis, and overall risk of bias showed significant associations between the groups in terms of the incidence rates of CTCs, OS, and PFS. In addition, the results of risk differences based on sampling time showed that the use of the cell search method (RD: − 0.19, 95%CI (− 0.28, − 0.10), p < 0.001), epithelial marker (RD: − 0.12, 95%CI (− 0.25, 0.00), p 0.05) and mesenchymal markers (RD: − 0.35, 95%CI (− 0.57, − 0.13), p 0.002) before the treatment might have a higher diagnostic power to identify CTCs and also chemotherapy treatment (RD: − 0.17, 95%CI (− 0.31, − 0.03), p 0.016) could significantly reduce the number of CTCs after the treatment. We also found that the risk differences between the clinical early and advanced stages were not statistically significant (RD: − 0.10, 95%CI (− 0.23, 0.02), P 0.105). Also, in the Lauren classification, the incidence of CTC in the diffuse type (RD: − 0.19, 95%CI (− 0.37, − 0.01), P0.045) was higher than that in the intestinal type. Meta-regression analysis showed that baseline characteristics were not associated with the detection of CTCs in GC patients. According to our systematic review and meta-analysis, CTCs identification may be suggested as a diagnostic technique for gastric cancer screening, and the outcomes of CTC detection may also be utilized in the future to create personalized medicine programs. © The Author(s) 2024.